Real-world effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 infection: A multicenter, retrospective cohort study
Journal of Infection · 2024
DOI: 10.1016/j.jinf.2024.106355 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Infection, 2024. Verfasst von Zhigang Ren und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou Universit…. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, COVID-19, Hospitalization, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
OBJECTIVES: Azvudine has been designated as a priority treatment for patients infected with SARS-CoV-2, however, clinical evidence in hospitalized cases remains insufficient. METHODS: We performed a multi-center, retrospective cohort study to evaluate the effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 in China (NCT06349655). Kaplan-Meier method, Cox regression model, subgroup analysis, and seven sensitive analyses were employed. RESULTS: A total of 32864 hospitalized patients with SARS-CoV-2 were enrolled, in which 5735 azvudine recipients and 5735 controls were selected using 1:1 propensity score matching. Based on Kaplan-Meier analysis, azvudine significantly reduced rates of all-cause death (P < 0.0001) and composite disease progression (P = 0.00019). Cox regression analysis demonstrated that hazard ratios of all-cause death and composite disease progression were 0.68 (95%CI: 0.598-0.775, P < 0.001) and 0.88 (95% CI: 0.795-0.976, P = 0.016), respectively. Subgroup analysis showed preference of azvudine for patients receiving antibiotics in reducing all-cause death and composite disease progression. Seven sensitivity analyses verified the robustness of our results. Safety analysis on adverse events showed no significant difference between both groups. CONCLUSIONS: This study suggested that azvudine may reduce all-cause death and composite disease progression in hospitalized patients with SARS-CoV-2 infection without serious adverse events. However, the findings are susceptible to some potential biases, and further studies still need to identify the efficacy of azvudine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Electronic address: fccrenzg@zzu.edu.cn.
- Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
- Department of Gastrointestinal Surgery, Nanyang Central Hospital, Nanyang 473009, China.
- Department of Cardiovascular Medicine, Henan Provincial Chest Hospital Affiliated to Zhengzhou University, Zhengzhou 450008, China.
- Department of Respiratory and Critical Care Medicine, Fengqiu County People's Hospital, Xinxiang 453300, China.
- Henan Center for Disease Control and Prevention, Zhengzhou 450016, China.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Ren, Z., Yang, M., Su, G., Qian, G., Yuan, Y., Yu, J., Li, S., Wang, C., Lu, M., Luo, H., Zhang, S., Li, G., Zhang, D., Wang, L., Li, G., Jin, X., Wang, J., Wang, M., Cheng, M., …, & Yu, Z. (2024). Real-world effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 infection: A multicenter, retrospective cohort study. Journal of Infection. https://doi.org/10.1016/j.jinf.2024.106355
Vancouver
Ren Z, Yang M, Su G, Qian G, Yuan Y, Yu J, et al. Real-world effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 infection: A multicenter, retrospective cohort study. Journal of Infection. 2024. doi:10.1016/j.jinf.2024.106355
BibTeX
@article{Ren2024,
author = {Ren, Zhigang and Yang, Mengzhao and Su, Guanyue and Qian, Guowu and Yuan, Yiqiang and Yu, Jia and Li, Silin and Wang, Changshuang and Lu, Mingxia and Luo, Hong and Zhang, Shixi and Li, Guangming and Zhang, Donghua and Wang, Ling and Li, Guotao and Jin, Xiaoli and Wang, Juan and Wang, Mingming and Cheng, Ming and Wang, Haiyu and Chang, Junbiao and Yu, Zujiang},
title = {Real-world effectiveness and safety of azvudine in hospitalized patients with SARS-CoV-2 infection: A multicenter, retrospective cohort study},
journal = {Journal of Infection},
year = {2024},
doi = {10.1016/j.jinf.2024.106355}
}
EUVIMED